[Prognostic analysis of 336 patients with chronic severe hepatitis B]

Jian-Chun Guo1, Chuan-Rong Duan, Yun-Hao Xun

  • 1Hangzhou 6th Hospital, Hangzhou 310014, China. guojianchunl96@126.com

Insights

Antivirus therapy can reduce the death rate in chronic severe hepatitis B (CSHB) patients. Factors like age, prothrombin activity, and complication severity also impact CSHB prognosis.

Area of Science:

  • Hepatology
  • Virology
  • Internal Medicine

Context:

  • Chronic severe hepatitis B (CSHB) presents a significant global health challenge.
  • Identifying prognostic factors is crucial for managing CSHB patients.
  • Retrospective analysis of 336 CSHB patients provides insights into survival outcomes.

Purpose:

  • To investigate risk factors influencing the prognosis of chronic severe hepatitis B.
  • To identify key indicators for predicting patient outcomes in CSHB.

Summary:

  • Age, prothrombin activity (PTA), and the number of complications were significant risk factors for CSHB mortality.
  • Antivirus therapy emerged as a significant protective factor, reducing the death rate.
  • Sex, family history, and treatments like artificial liver support system (ALSS) or alprostadil did not show significant impact on prognosis.

Impact:

  • This study highlights the critical role of antivirus therapy in improving CSHB outcomes.
  • Understanding these risk factors can guide clinical decision-making and treatment strategies for CSHB.
  • Findings contribute to better patient management and potentially reduced mortality in chronic severe hepatitis B.
Abstract

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...